Zyla Life Sciences (OTCQX: ZCOR) ("Zyla"), a commercial-stage life sciences company, announced yesterday that it has named Todd N Smith as its new president, chief executive officer and director, effective immediately.

Smith replaces Robert Radie, who has resigned as president, chief executive officer and director of the company to pursue other opportunities.

Smith has more than 25 years of experience in the biopharmaceutical industry. Before joining the company, from 2017 to February 2019, he served as chief executive officer and a director of Iroko Pharmaceuticals Inc, from which the company purchased five products in early 2019. During the period October 2014 until June 2015, he served as the chief commercial officer of Ophthotech Corporation. Since 2014, he has also held multiple senior roles at privately owned pharmaceutical and medical device companies. Additionally, he has held a variety of senior commercial and marketing roles at organisations including Horizon Therapeutics plc, a public biopharmaceutical company focused on rare and rheumatic diseases, and Abbott, a public healthcare products company.

Timothy P Walbert, chairman of the board, Zyla, said, 'On behalf of the board, I want to thank Bob for his contributions and service to Zyla and its leadership team during the last seven years. I would also like to welcome Todd Smith to the Company. He is an accomplished executive with significant experience driving deal making and commercial success in different therapeutic areas and I am confident that he will continue that track record at Zyla.'